Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Giant Cell Arteritis (GCA) Clinical Trial

Official title:
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg and 150 mg Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) (GCAptAIN)

Status Recruiting

Clinical Trial Summary

This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)

Clinical Trial Description

Randomized, parallel-group, double-blind, placebo-controlled, multi-center, Phase III study to evaluate the efficacy of secukinumab in combination with a 26-week prednisone taper regimen compared to pllacebo in combination with a 52-week prednisone taper regimen ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04930094
Study type	Interventional
Source	Novartis
Contact	Novartis Pharmaceuticals
Phone	1-888-669-6682
Email	novartis.email@novartis.com
Status	Recruiting
Phase	Phase 3
Start date	October 6, 2021
Completion date	July 2, 2027

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05479448` - Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis
	Active, not recruiting	`NCT03725202` - A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis	Phase 3